ReviewZhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery2026
[Bifunctional biomaterials: An innovative strategy for synergistic bone tumor therapy and bone regeneration].
Review in Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To review research progress of bifunctional biomaterials in the treatment of bone tumors and bone defects in recent years, aiming to provide assistance for the further research of bifunctional biomaterials. Methods: A wide range of domestic and international literature on the preparation and properties of novel bifunctional biomaterials in recent years was reviewed, followed by summary and analysis. Carrier-functionalized materials, intrinsically active materials, and immune-engineered materials were summarized respectively, and discussions were conducted from aspects such as anti-tumor effects and controlled drug release. Results: Studies have revealed that, unlike traditional biomaterials, the novel bifunctional biomaterials can effectively inhibit the Conclusion: Novel multifunctional biomaterials can inhibit bone tumor cells and promote new bone formation at the site of bone defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.